Tetracosactide

	WikiDoc Resources for Tetracosactide
Articles
Most recent articles on Tetracosactide Most cited articles on Tetracosactide Review articles on Tetracosactide Articles on Tetracosactide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Tetracosactide Images of Tetracosactide Photos of Tetracosactide Podcasts & MP3s on Tetracosactide Videos on Tetracosactide
Evidence Based Medicine
Cochrane Collaboration on Tetracosactide Bandolier on Tetracosactide TRIP on Tetracosactide
Clinical Trials
Ongoing Trials on Tetracosactide at Clinical Trials.gov Trial results on Tetracosactide Clinical Trials on Tetracosactide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Tetracosactide NICE Guidance on Tetracosactide NHS PRODIGY Guidance FDA on Tetracosactide CDC on Tetracosactide
Books
Books on Tetracosactide
News
Tetracosactide in the news Be alerted to news on Tetracosactide News trends on Tetracosactide
Commentary
Blogs on Tetracosactide
Definitions
Definitions of Tetracosactide
Patient Resources / Community
Patient resources on Tetracosactide Discussion groups on Tetracosactide Patient Handouts on Tetracosactide Directions to Hospitals Treating Tetracosactide Risk calculators and risk factors for Tetracosactide
Healthcare Provider Resources
Symptoms of Tetracosactide Causes & Risk Factors for Tetracosactide Diagnostic studies for Tetracosactide Treatment of Tetracosactide
Continuing Medical Education (CME)
CME Programs on Tetracosactide
International
Tetracosactide en Espanol Tetracosactide en Francais
Business
Tetracosactide in the Marketplace Patents on Tetracosactide
Experimental / Informatics
List of terms related to Tetracosactide

Tetracosactide
Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a605020
ATC code	H01AA02 (WHO) ;
Identifiers
CAS Number	16960-16-0 ;
PubChem CID	16129617;
ChemSpider	10481947 ;
UNII	72YY86EA29;
KEGG	D00284 ;
ChEBI	CHEBI:3901 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C136H210N40O31S
Molar mass	2933.44 g/mol
	InChI InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86?,88-,89-,90+,91-,92+,93+,94+,95+,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,109+,110+,111+/m1/s1 ; Key:ZOEFCCMDUURGSE-CQVUSSRSSA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tetracosactide (marketed under the brand name Synacthen) is a synthetic analogue consisting of the first 24 amino acids of the naturally occurring adrenocorticotrophic hormone (ACTH). It is known to be used as a doping agent to increase the secretion of glucocorticoids by adrenal glands.^[1]

Pharmacology

In the normal situation, ACTH is released from the pituitary gland at the base of the brain. It acts on the adrenal glands to stimulate the production of steroid hormones (glucocorticoids). If the adrenal glands are healthy, a single injection of tetracosactide results in a rise in blood cortisol (hydrocortisone) concentrations in 30 minutes. If the adrenal glands appear not to be working then tetracosactide injection can be given to check whether the problem is due to diseased or damaged adrenals or due to lack of pituitary ACTH.

Uses

This medication is used for diagnostic purposes only (e.g. in short synacthen test). It is suitable for treatment of adrenal insufficiency of central origin.

As well as its legitimate medical applications, it has been widely reported that Synacthen has also been used as an illegal performance enhancing drug by professional cyclists.^[2]

It has been used in the treatment of infantile spasms.^[3]

References

↑ Chaabo A, de Ceaurriz J, Buisson C, Tabet JC, Lasne F (February 2011). "Simultaneous quantification and qualification of synacthen in plasma". Anal Bioanal Chem. 399 (5): 1835–43. doi:10.1007/s00216-010-4565-z. PMID 21170520.
↑ Kimmage P (2007). "tour 87 stage 14". Rough Ride. Yellow Jersey Press. p. 125. ISBN 0-224-08017-2.
↑ Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP (2004). "The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial". Lancet. 364 (9447): 1773–8. doi:10.1016/S0140-6736(04)17400-X. PMID 15541450.

Template:Pituitary and hypothalamic hormones and analogues

[pmid21170520-1] Chaabo A, de Ceaurriz J, Buisson C, Tabet JC, Lasne F (February 2011). "Simultaneous quantification and qualification of synacthen in plasma". Anal Bioanal Chem. 399 (5): 1835–43. doi:10.1007/s00216-010-4565-z. PMID 21170520.

[isbn0-224-08017-2-2] Kimmage P (2007). "tour 87 stage 14". Rough Ride. Yellow Jersey Press. p. 125. ISBN 0-224-08017-2.

[pmid15541450-3] Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP (2004). "The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial". Lancet. 364 (9447): 1773–8. doi:10.1016/S0140-6736(04)17400-X. PMID 15541450.

[1]

[2]

[3]

Tetracosactide

Overview

Pharmacology

Uses

See also

References

Navigation menu

Tetracosactide

Overview

Pharmacology

Uses

See also

References

Navigation menu

Search